Medscape
The US Food and Drug Administration (FDA) has approved nemolizumab for moderate-to-severe atopic dermatitis inadequately controlled with topical therapies in patients aged 12 years and older, according to a press release from the manufacturer, Galderma. Nemolizumab (Nemluvio), a monoclonal antibody administered subcutaneously, targets the interleukin-31 (IL-31) receptor…
Read More
Nemolizumab Gets FDA Nod for Atopic Dermatitis
Joan Lanz
14:27
The US Food and Drug Administration (FDA) has approved nemolizumab for moderate-to-severe atopic dermatitis inadequately controlled with topical therapies in patients aged 12 years and older, according to a press release from the manufacturer, Galderma. Nemolizumab (Nemluvio), a monoclonal antibody administered subcutaneously, targets the interleukin-31 (IL-31) receptor…
